Bibliography
- Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012;11(3):459-71
- FDA. Guidance for the clinical evaluation of weight-control drugs. Crit Rev Food Sci Nutr 2001;41(1):91-4
- Mayor S. NICE requires primary care trusts to tackle prevention and management of obesity. Bmj 2006;333(7581):1239
- Rucker D, Padwal R, Li SK, Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Bmj 2007;335(7631):1194-9
- Bello NT, Liang NC. The use of serotonergic drugs to treat obesity–is there any hope? Drug Des Devel Ther 2011;5:95-109
- FDA. NDA 22529 Lorcaserin Hydrochloride Tablets, 10 mg Briefing Document, 2012(10-May-2012)
- Launay JM, Herve P, Peoc'h K, Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8(10):1129-35
- Nebigil CG, Hickel P, Messaddeq N, Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation 2001;103(24):2973-9
- FDA. NDA 22580 VI-0521 (Qnexa) Briefing Document 2012(22-Feb-2012)
- Rothman RB, Hendricks EJ. Phentermine cardiovascular safety. Am J Emerg Med 2009;27(8):1010-13
- Bray GA, Hollander P, Klein S, A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11(6):722-33
- Lannett Company I. Phentermine Hydrochloride tablet (37.5 mg), Revised 04/2012, Revision 2. Package Insert 2012
- FDA. Risk of oral clefts in children born to mothers taking Topamax (topiramate)[03-04-2011] Drug Safety Communication, 2011(07-March-2011)
- Sachdev M, Miller WC, Ryan T, Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002;144(6):1065-73
- Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305(19):1996-2002